ClinicalTrials.gg
RecruitingNCT07286656Updated Feb 17, 2026

A Study of GensSci098 in Subjects With Graves' Disease

A Phase 1 interventional study of GenSci098 in Safety, Tolerability and GenSci098, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Graves Disease with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Graves Disease · China.

Planned enrollment
6th of 10
24 · median 37
Started
2025
with 2 others
Phase 1
5 of 19
4 open now
Registered
16th of 19
by date
Lead sponsor
1 of 19
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 19 studies in Graves Disease with a site in China, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 16th registered.

Graves Disease

162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.

Browse Graves Disease studies →

Open to participants now

10 of the 19 studies in Graves Disease with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Graves Disease with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease

03

Conditions studied

  • Safety
  • Tolerability
  • GenSci098
  • Graves Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Voluntary signed .
  • Confirmed diagnosis of diffuse toxic goiter (Graves' disease).
  • Abnormal thyroid function tests (e.g., elevated T4, and suppressed TSH).
  • No prior or recent use of antithyroid medications (discontinued for at least 4 weeks).
  • Female participants must be , surgically sterile, or using a highly effective method of .
  • Male participants must agree to practice abstinence, use a highly effective method of contraception, or have undergone vasectomy.
  • Ability to comply with the follow-up schedule and understand and adhere to the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Non-diffuse toxic goiter-induced hyperthyroidism.
  • Previous radioactive iodine treatment or thyroid surgery.
  • History or risk of thyroid storm.
  • Use of thyroid hormone medications within the past 6 weeks.
  • accompanied by active thyroid eye disease.
  • Thyroid eye disease treated with radiation/surgery,or need for urgent surgery surgical or medical intervention.
  • Optic nerve lesions or corneal damage.
  • Use of or within the past 3 months,or those who have used biologics within 6 months
  • Inability to quit smoking during the study.
  • Allergy to the study drug or monoclonal antibodies.
  • Participation in another clinical trial within the past 3 months.
  • Abnormal .
  • Significant hepatic or renal dysfunction.
  • Pregnancy,breastfeeding,or positive pregnancy test.
  • Positive for ,syphilis,,or .
  • History of drug or substance abuse.
  • Other diseases requiring treatment.
  • History of malignant tumors.
  • Splenectomy or major surgery within the past 6 months.
  • Severe cardiovascular,pulmonary,hepatic,renal,neurological,or hematological diseases.
  • Other conditions deemed unsuitable by investigators.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    GenSci098

    Drug: GenSci098

Interventions

  • DrugGenSci098

    * Administration: Only one dose of GenSci098 will be given. * Route of Administration: Subcutaneous (injected under the skin). * Dose Levels: • Dose 1 • Dose 2• Dose 3• Dose 4

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs) (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG]).

    This outcome measure assesses the incidence and severity of adverse events (AEs) experienced by participants during the study. AEs will be monitored through physical examinations, vital signs, laboratory tests, and 12-lead electrocardiograms (ECGs). The assessment period spans from the first dose of the study intervention to 141 days post-dosing.

    Time frame: 141 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Oct 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 16, 2025
StartActual
Nov 21, 2025
Primary completionEst.
Oct 28, 2026
CompletionEst.
Mar 18, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07286656
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Nov 21, 2025
Primary completion
Oct 28, 2026 (estimated)
Completion
Mar 18, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Zhongyan Shan, PHD
Contact
shanzhongyan@hotmail.com
+86 24 8328 2152
Zhongyan Shan, PHD
principal investigator · First Hospital of China Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion